Quantitative immunohistochemistry analysis of breast Ki67 based on artificial intelligence.

Journal: Open life sciences
Published Date:

Abstract

Breast cancer is a common malignant tumor of women. Ki67 is an important biomarker of cell proliferation. With the quantitative analysis, it is an important indicator of malignancy for breast cancer diagnosis. However, it is difficult to accurately and quantitatively evaluate the count of positive nucleus during the diagnosis process of pathologists, and the process is time-consuming and labor-intensive. In this work, we employed a quantitative analysis method of Ki67 in breast cancer based on deep learning approach. For the diagnosis of breast cancer, according to breast cancer diagnosis guideline, we first identified the tumor region of Ki67 pathological image, neglecting the non-tumor region in the image. Then, we detect the nucleus in the tumor region to determine the nucleus location information. After that, we classify the detected nucleuses as positive and negative according to the expression level of Ki67. According to the results of quantitative analysis, the proportion of positive cells is counted. Combining the above process, we design a breast Ki67 quantitative analysis pipeline. The Ki67 quantitative analysis system was assessed on the validation set. The Dice coefficient of the tumor region segmentation model was 0.848, the Average Precision index of the nucleus detection model was 0.817, and the accuracy of the nucleus classification model was 96.66%. Besides, in clinical independent sample experiment, the results show that the proposed breast Ki67 quantitative analysis system achieve excellent correlation with the diagnosis efficiency of doctors improved more than ten times and the overall consistency of diagnosis is intra-group correlation coefficient: 0.964. The research indicates that our quantitative analysis method of Ki67 in breast cancer has high clinical application value.

Authors

  • Wenhui Wang
    Department of Pathology, Hangzhou Women's Hospital, Hangzhou, 310008, Zhejiang, China.
  • Yitang Gong
    Department of Pathology, Hangzhou Women's Hospital, Hangzhou, 310008, Zhejiang, China.
  • Bingxian Chen
    Ningbo Konfoong Bioinformation Tech Co., Ltd, Ningbo, China.
  • Hualei Guo
    Department of Pathology, Hangzhou Women's Hospital, Hangzhou, 310008, Zhejiang, China.
  • Qiang Wang
    Ningbo Konfoong Bioinformation Tech Co., Ltd, Ningbo, China.
  • Jing Li
    Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, China.
  • Cheng Jin
    Department of Pathology, Hangzhou Women's Hospital, Hangzhou, 310008, Zhejiang, China.
  • Kun Gui
    Ningbo Konfoong Bioinformation Tech Co., Ltd, Ningbo, China.
  • Hao Chen
    The First School of Medicine, Wenzhou Medical University, Wenzhou, China.

Keywords

No keywords available for this article.